We use cookies for a better user experience. Read our Privacy Policy

I Agree

Head and Neck Cancer Market

Head and Neck Cancer Market (Drug Class - EFGR Inhibitors, Mitotic Inhibitors, Anti-PD-1 Monoclonal Antibodies; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

Global Head and Neck Cancer Market – Snapshot

The global head and neck cancer market is driven by increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, surge in research and development activity, increase in product approvals, and rise in government initiatives. An estimated 75% of head and neck cancers is caused due to consumption of alcohol and tobacco. However, high cost of treatment and high failure rate of late stage clinical trials are the major factors restraining the global market.

Head and Neck Cancer

The global head and neck cancer market has been segmented based on drug class, distribution channel, and region. In terms of drug class, the global market has been classified into EFGR inhibitors, mitotic inhibitors, anti-PD-1 monoclonal antibodies, and others. The anti-PD-1 monoclonal antibodies segment is projected to account for major share of the market by the end of the forecast period. Increase in research and development activity in the pharmaceutical industry, development of new products, and rise in mergers & acquisitions are expected to drive the segment during the forecast period. Based on distribution channel, the global head and neck cancer market has been classified into hospital pharmacies, retail pharmacies, and e-commerce. In terms of region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on drug class, the anti-PD-1 monoclonal antibodies segment is anticipated to dominate the global head and neck cancer market. Increase in awareness, rise in demand for efficient drugs for treatment, and new product approvals are expected to propel the segment during the forecast period. For instance, in November 2016, Bristol-Myers Squibb received the FDA approval for Opdivo (nivolumab) for intravenous treatment of individuals with metastatic squamous cell carcinoma of the head and neck (SCCHN)

In terms of distribution channel, the hospital pharmacies segment dominated the global head and neck cancer market. Increase in patient population and improvement in health care infrastructure are expected to drive the segment during the forecast period.

North America accounted for the largest share of the global market in 2017. Rise in prevalence of head and neck cancer (HNC), surge in health care expenditure, growth of the pharmaceutical industry, rise in mergers & acquisitions, and robust product pipeline are anticipated to drive the market in the region during the forecast period. Rise in demand for efficient drugs for treatment of HNCs in emerging economies such as China and India, growing pharmaceutical industry, and rapidly increasing patient population are anticipated to fuel the growth of the market in Asia Pacific during the forecast period. The head and neck cancer market in Latin America and Middle East & Africa is expected to be driven by rise in government initiatives to promote better health care facilities and increase in investment in health care sector during the forecast period. Growth of the health care industry, increase in the number of pharmaceutical companies, and rise in demand for therapeutics are expected to augment the market in these regions during the forecast period.

Major players operating in the global head and neck cancer market include Sanofi, Pfizer, Eli Lilly and Company, Merck KgaA, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals. Increase in mergers & acquisitions, new product development, and strategic collaboration between major companies and governing authorities are expected to drive the global market during the forecast period. In October 2018, Sanofi received the FDA approval for TAXOTERE for the treatment of patients with head and neck cancer.

The global head and neck cancer market has been segmented as below:

Drug Class

  • EGFR Inhibitors
  • Mitotic Inhibitors
  • Anti-PD-1 Monoclonal Antibodies
  • Others

Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • E-commerce

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Head and Neck Cancer Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes


1. Preface
   1.1. Market Definition and Scope
   1.2. Market Segmentation
   1.3. Key Research Objectives
   1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Head and Neck Cancer (HNC) Market

4. Market Overview
   4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments
   4.2. Overview
   4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
   4.4. Global Head and Neck Cancer (HNC) Market Analysis and Forecasts, 2016–2026
        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
   5.1. Key Mergers & Acquisitions
   5.2. Pipeline Analysis

6. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Drug Class
   6.1. Introduction & Definition
   6.2. Key Findings / Developments
   6.3. Market Value Forecast, by Drug Class, 2016–2026
        6.3.1. EGFR Inhibitors
        6.3.2. Mitotic Inhibitors
        6.3.3. Anti-PD-1 Monoclonal Antibodies
        6.3.4. Others
   6.4. Market Attractiveness by Drug Class

7. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Distribution Channel
   7.1. Introduction & Definition
   7.2. Key Findings / Developments
   7.3. Market Value Forecast, by Distribution Channel, 2016–2026
        7.3.1. Hospitals Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. E-commerce
   7.4. Market Attractiveness, by Distribution Channel

8. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Region
   8.1. Key Findings
   8.2. Market Value Forecast, by Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
   8.3. Market Attractiveness, by Country/Region

9. North America Head and Neck Cancer (HNC) Market Analysis and Forecast
   9.1. Introduction
        9.1.1. Key Findings
   9.2. Market Value Forecast, by Drug Class, 2016–2026
        9.2.1. EGFR Inhibitors
        9.2.2. Mitotic Inhibitors
        9.2.3. Anti-PD-1 Monoclonal Antibodies
        9.2.4. Others
   9.3. Market Value Forecast, by Distribution Channel, 2016–2026
        9.3.1. Hospitals Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. E-commerce
   9.4. Market Value Forecast, by Country, 2016-2026
        9.4.1. U.S.
        9.4.2. Canada
   9.5. Market Attractiveness Analysis
        9.5.1. By Drug Class
        9.5.2. By Distribution Channel
        9.5.3. By Country

10. Europe Head and Neck Cancer (HNC) Market Analysis and Forecast
   10.1. Introduction
        10.1.1. Key Findings
   10.2. Market Value Forecast, by Drug Class, 2016–2026
        10.2.1. EGFR Inhibitors
        10.2.2. Mitotic Inhibitors
        10.2.3. Anti-PD-1 Monoclonal Antibodies
        10.2.4. Others
   10.3. Market Value Forecast, by Distribution Channel, 2016–2026
        10.3.1. Hospitals Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. E-commerce
   10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
   10.5. Market Attractiveness Analysis
        10.5.1. By Drug Class
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region

11. Asia Pacific Head and Neck Cancer (HNC) Market Analysis and Forecast
   11.1. Introduction
        11.1.1. Key Findings
   11.2. Market Value Forecast, by Drug Class, 2016–2026
        11.2.1. EGFR Inhibitors
        11.2.2. Mitotic Inhibitors
        11.2.3. Anti-PD-1 Monoclonal Antibodies
        11.2.4. Others
   11.3. Market Value Forecast, by Distribution Channel, 2016–2026
        11.3.1. Hospitals Pharmacies
        11.3.2. Retail Pharmacies
        11.3.3. E-commerce
   11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
        11.4.1. China
        11.4.2. India
        11.4.3. Japan
        11.4.4. Australia & New Zealand
        11.4.5. Rest of APAC
   11.5. Market Attractiveness Analysis
        11.5.1. By Drug Class
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region

12. Latin America Head and Neck Cancer (HNC) Market Analysis and Forecast
   12.1. Introduction
        12.1.1. Key Findings
   12.2. Market Value Forecast, by Drug Class, 2016–2026
        12.2.1. EGFR Inhibitors
        12.2.2. Mitotic Inhibitors
        12.2.3. Anti-PD-1 Monoclonal Antibodies
        12.2.4. Others
   12.3. Market Value Forecast, by Distribution Channel, 2016–2026
        12.3.1. Hospitals Pharmacies
        12.3.2. Retail Pharmacies
        12.3.3. E-commerce
   12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of LATAM
   12.5. Market Attractiveness Analysis
        12.5.1. By Drug Class
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region

13. Middle East & Africa Head and Neck Cancer (HNC) Market Analysis and Forecast
   13.1. Introduction
        13.1.1. Key Findings
   13.2. Market Value Forecast, by Drug Class, 2016–2026
        13.2.1. EGFR Inhibitors
        13.2.2. Mitotic Inhibitors
        13.2.3. Anti-PD-1 Monoclonal Antibodies
        13.2.4. Others
   13.3. Market Value Forecast, by Distribution Channel, 2016–2026
        13.3.1. Hospitals Pharmacies
        13.3.2. Retail Pharmacies
        13.3.3. E-commerce
   13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of MEA
   13.5. Market Attractiveness Analysis
        13.5.1. By Drug Class
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region

14. Competition Landscape
   14.1. Market Player - Competition Matrix (By Tier and Size of companies)
   14.2. Market Share Analysis, by Company (2017)
   14.3. Company Profiles
        14.3.1. Sanofi
               14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.1.2. Financial Overview
               14.3.1.3. Product Portfolio
               14.3.1.4. SWOT Analysis
               14.3.1.5. Strategic Overview
        14.3.2. Pfizer
               14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.2.2. Financial Overview
               14.3.2.3. Product Portfolio
               14.3.2.4. SWOT Analysis
               14.3.2.5. Strategic Overview
        14.3.3. Eli Lilly and Company
               14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.3.2. Financial Overview
               14.3.3.3. Product Portfolio
               14.3.3.4. SWOT Analysis
               14.3.3.5. Strategic Overview
        14.3.4. AstraZeneca
               14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.4.2. Financial Overview
               14.3.4.3. Product Portfolio
               14.3.4.4. SWOT Analysis
               14.3.4.5. Strategic Overview
        14.3.5. Teva Pharmaceuticals
               14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.5.2. Financial Overview
               14.3.5.3. Product Portfolio
               14.3.5.4. SWOT Analysis
               14.3.5.5. Strategic Overview
        14.3.6. F. Hoffmann-La Roche Ltd.
               14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.6.2. Financial Overview
               14.3.6.3. Product Portfolio
               14.3.6.4. SWOT Analysis
               14.3.6.5. Strategic Overview
        14.3.7. Fresenius Kabi
               14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.7.2. Financial Overview
               14.3.7.3. Product Portfolio
               14.3.7.4. SWOT Analysis
               14.3.7.5. Strategic Overview
        14.3.8. Merck
               14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.8.2. Financial Overview
               14.3.8.3. Product Portfolio
               14.3.8.4. SWOT Analysis
               14.3.8.5. Strategic Overview
        14.3.9. Bayer AG
               14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.9.2. Financial Overview
               14.3.9.3. Product Portfolio
               14.3.9.4. SWOT Analysis
               14.3.9.5. Strategic Overview
        14.3.10. Bristol-Myers Squibb Company
               14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.10.2. Financial Overview
               14.3.10.3. Product Portfolio
               14.3.10.4. SWOT Analysis
               14.3.10.5. Strategic Overview
        14.3.11. Galera
               14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.11.2. Financial Overview
               14.3.11.3. Product Portfolio
               14.3.11.4. SWOT Analysis
               14.3.11.5. Strategic Overview

 

List of Tables

Table 01: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 03: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
Table 05: North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel,
Table 07: Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 09: Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 12: Asia Pacific Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 14: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class (2017)
Figure 03: Global Head and Neck Cancer (HNC) Market Value Share (%), by Distribution Channel (2017)
Figure 04: Global Head and Neck Cancer (HNC) Market Value Share (%), by Region (2017) 
 Figure 05: Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 06: Global Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 07: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EGFR Inhibitors, 2016–2026
Figure 08: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Mitotic Inhibitors, 2016–2026
Figure 09: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-PD-1 Monoclonal Antibodies, 2016–2026
Figure 10: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others,
Figure 11: Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 12: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by
Figure 13: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 14: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016–2026
Figure 15: Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 16: Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Region, 2018 and 2026
Figure 17: Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Region, 2018–2026
Figure 18: North America Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 19: North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country, 2018 and 2026
Figure 20: North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country, 2018–2026
 Figure 21: North America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 22: North America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 23: North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 24: North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 25: Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 27: Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
 Figure 28: Europe Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 29: Europe Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 30: Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 31: Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 32: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 33: Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 34: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
 Figure 35: Asia Pacific Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 36: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 37: Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 38: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 39: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 40: Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 41: Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
 Figure 42: Latin America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 43: Latin America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 44: Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 45: Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
Figure 46: Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, 2016–2026
Figure 47: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 48: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
 Figure 49: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
Figure 50: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
Figure 51: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 52: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 53: Global Head and Neck Cancer (HNC) Market Share, by Company, 2017
Figure 54: AstraZeneca Oncology Business Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
Figure 55: AstraZeneca R&D in Oncology Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
Figure 56: AstraZeneca's Oncology Business Segment Revenue (% Share), by Region, 2017
Figure 57: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 58: Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
Figure 59: Eli Lilly and Company Breakdown of Net Sales, by Business Segment, 2017
Figure 60: Eli Lilly and Company Research and Development Cost, 2016 and 2017 (US$ Mn)
Figure 61: Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 62: Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 64: Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
Figure 64: Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
Figure 66: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 67: Novartis AG Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 68: Novartis AG’s Net Sales (% Share), by Business Segment, 2017
Figure 69: Novartis AG’s Net Sales (% Share), by Region, 2017
Figure 70: Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
Figure 71: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
Figure 72: Bristol-Myers Squibb Company Revenue, by Geography, 2017
Figure 73: Bayer AG Pharmaceutical Business Segment Revenue (US$ Bn), 2015-2017
Figure 74: Bayer AG Pharmaceutical Business Segment R&D Expenditure (US$ Bn), 2015-2017
Figure 75: Bayer AG Pharmaceutical Business Segment Revenue, by Geography (2017)
Figure 76: F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
Figure 77: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
Figure 78: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Specialty (2017)
Figure 79: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Region (2017)
Figure 80: Sanofi Revenue (US$ Bn), 2014-2017
Figure 81: Sanofi Regional Sales Breakdown (%), 2017
Figure 82: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 83: Teva Pharmaceutical Industries Ltd. Segmental Revenue (US$ Bn), 2017
Figure 84: Fresenius SE & Co. KGaA Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 85: Fresenius SE & Co. KGaA Breakdown of Net Sales (%), by Business Segment, 2017
Figure 86: Merck KGaA Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 87: Merck KGaA Revenue, by Geography (%), 2017
Figure 88: Merck KGaA Revenue, by Business Segment (%), 2014–2017

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

227

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved